Historically, ecstasy tablets contained 3,4-methylenedioxymethamphetamine (MDMA) as the psychoactive component. In recent years, the Drug Enforcement Administration (DEA) and other law enforcement agencies have seized ecstasy tablets that are comprised of psychoactive drugs or drug mixtures other than MDMA. Many jurisdictions have reported the presence of piperazine derivatives including 1-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)-piperazine (TFMPP), and 1-(3-chlorophenyl)-piperazine (mCPP) in ecstasy tablets. These piperazine derivatives produce stimulant and psychoactive effects similar to those produced by MDMA, amphetamine, and methamphetamine. In many countries, their use is not controlled, and therefore they have become a legal alternative to MDMA. For this study, a targeted population of 251 MDMA-positive urine samples were analyzed for designer drugs, including the piperazine derivatives. A basic liquid-liquid extraction followed by pentafluoropropionic anhydride (PFPA) derivatization and a full scan (m/z 42-550) gas chromatography-mass spectrometry analysis was used to screen the urine samples for 33 designer drugs. Overall, in 36% of the specimens analyzed, a stimulant or psychoactive compound other than MDMA and 3,4-methylenedioxyamphetamine (MDA) was detected. BZP, TFMPP, and mCPP were detected in 15%, 7%, and 1% of the samples, respectively.
Introduction
Historically, ecstasy tablets contained only 3,4-methylenedioxymethamphetamine (MDMA). However, in recent years, a large percentage of seized ecstasy tablets do not contain MDMA as their primary ingredient (1) . In some instances, they do not contain MDMA at all, but instead a mixture of other compounds. As many as eight different compounds have been detected in one seized tablet (1) . Some of the compounds detected in ecstasy tablets include methamphetamine, 1-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)-piperazine (TFMPP), 1-(3-chlorophenyl)-piperazine (mCPP), cocaine, dextromethorphan, and ketamine (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The most commonly found of these compounds are the piperazine derivatives: BZP, TFMPP, and mCPP. According to the Georgia Bureau of Investigation (GBI) in 2008, MDMA was the primary ingredient in 37% of ecstasy tablets, and a combination of BZP, TFMPP, and mCPP were the primary ingredients in 33% of ecstasy tablets (1) . In the following year they reported, that the primary ingredients of ecstasy tablets were MDMA at 35% and a combination of BZP, TFMPP, and mCPP at 59% (1) . Therefore, based on the GBI data, between 2008 and 2009, the ecstasy combination tablets containing MDMA as the primary ingredient remained consistent, and the percentage of tablets containing BZP, TFMPP, and mCPP as the primary ingredient almost doubled.
The use of piperazine derivatives such as BZP, TFMPP, and mCPP has become increasingly popular because of their euphoric effects. Their popularity is evident by the sheer number of confiscations throughout American law enforcement agencies and by their over-the-counter availability in countries where such compounds are legal (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) 17, 18) . These piperazine derivatives are available for purchase on the internet or in head shops in liquid, powder, or tablet form (18, 19) . They are commonly marketed as a 'party pill', ecstasy mimic tablet, or ecstasy combination pill (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) 17, 18) .
Previous work at the Division of Forensic Toxicology (DFT), The Armed Forces Medical Examiner System (AFMES), was conducted on 80 specimens that screened positive and confirmed negative for amphetamines. It was of interest to determine if any designer drugs were present in these specimens that caused them to screen positive. After screening for both basic and designer drugs, these specimens were found to contain only over-the-counter compounds; designer drugs were not detected. Because of the negative results from the aforementioned study and reports of recent drug seizures of ecstasy combination and mimic tablets, a targeted study was conducted on MDMA-positive urine samples from three Department of Defense (DoD) drug testing laboratories. The goal was to determine if any of the 33 designer drugs, particularly BZP, TFMPP, and mCPP, were present in these samples.
Sample Population
A total of 251 urine specimens that previously confirmed positive for MDMA and/or MDA were submitted from three DoD drug testing laboratories.
Experimental

Reagents and materials
All solvents were high-performance liquid chromatography grade and purchased from Fisher Scientific (Pittsburgh, PA). Sodium phosphate monobasic and dibasic and concentrated glacial acetic acid were purchased from Sigma Chemicals (St. Louis, MO). Mepivicaine, ethylmorphine, BZP, and TFMPP oxalate were purchased from Sigma-Aldrich (St. Louis, MO). mCPP hydrochloride and pentafluoropropionic anhydride (PFPA) were purchased from Aldrich (Milwaukee, WI). Concentrated hydrochloric acid (HCl) was purchased from EMD Chemicals (Gibbstown, NJ). Potassium hydroxide (KOH) pellets were purchased from Fisher Scientific. Methamphetamined 14 , mescaline-d 9 , and TFMPP-d 4 were purchased from Cerilliant (Round Rock, TX). Mixed-mode silica-based solid-phase extraction columns (ZCDAU020) were purchased from United Chemical Technologies (Bristol, PA).
Standards, calibrators, and control preparation
For the BZP and TFMPP extraction and quantitative procedure, stock standards of BZP, TFMPP, and mCPP were prepared in methanol and stored at -15°C in amber vials. Calibrator samples were prepared in 2.0 mL of certified drug-free urine by spiking BZP and TFMPP at concentrations of 0.025, 0.05, 0.20, 0.50, 1.0, and 2.0 mg/L. A urine control was prepared from the same stock standard sources in certified drugfree urine at 0.50 mg/L. Calibrator and control samples were prepared prior to each extraction. mCPP was prepared for use as the internal standard at a concentration of 0.01 mg/mL.
For the mCPP extraction and quantitative procedure, stock standards of mCPP and TFMPP-d 4 were prepared in methanol and stored at -15°C in amber vials. Calibrator samples were prepared in 2.0 mL of certified drug-free urine by fortifying samples with mCPP at concentrations of 0.025, 0.05, 0.20, 0.50, 1.0, and 2.0 mg/L. A urine control was prepared from the same stock standard source in certified drug-free urine at 0.50 mg/L. Calibrator and control samples were prepared prior to each extraction. TFMPP-d 4 was prepared for use as the internal standard at a concentration of 0.01 mg/mL.
Instumentation
Samples were screened and quantitated using an Agilent Technologies 6890 gas chromatograph (GC) coupled to a 5975 mass spectrometric (MS) detector (Palo Alto, CA). The separation columns were from J&W (20 m × 0.18 mm × 0.18 μm, Rancho Cordova, CA) with helium carrier gas maintained at a constant flow of 1.0 mL/min. The MS source and quadrupole temperatures were held at 230°C and 150°C, respectively. The transfer line was set to 280°C. 
Basic drug screen extraction
Two milliliters of sample was aliquoted, and 100 µL of the internal standard solution containing 0.01 mg/mL mepivacaine and ethylmorphine was added to each sample for a final concentration of 0.50 mg/L. Negative and positive urine samples were extracted with each batch. Next, 3 mL of 0.1 M phosphate buffer (pH 6.0) were added to each sample. Extraction columns were conditioned successively with 3 mL of methanol, 3 mL deionized water, and 2 mL of 0.1 M phosphate buffer (pH 6.0). Following sample application, the columns were washed with 2 mL of deionized water, 2 mL of 20% acetonitrile in deionized water, and 2 mL of 0.1 M acetic acid. The columns were dried under vacuum for 3 min. The final wash steps included 2 mL of hexane followed by 3 mL of methanol. The columns were dried under vacuum for 10 min. The analytes were eluted with 3 mL of dichloromethane/isopropanol/ammonium hydroxide (78:20:2) and eluates were evaporated under nitrogen at 25°C. The eluates were reconstituted in 50 μL of acetonitrile and transferred to glass autosampler vials.
Three microliters of sample was injected using a pulsed split program of 40 psi for 1.0 min, at a 10:1 split and an inlet temperature of 250°C. An initial oven temperature of 70°C was held for 1 min before ramping at 20°C/min to 300°C. The column was held for 5.0 min at the final temperature of 300°C for a total run time of 17.5 min.
The confirmation criteria for acceptance of a positive screening result are as follows: the retention time of a suspected analyte in a sample must be within ± 2% of the retention time of the analyte in the standards, and the mass spectrum must have a minimum match quality of 70% compared to the reference library spectrum.
Designer drug screen extraction
Three milliliters of sample was aliquoted, and 75 µL of the internal standard solution containing 0.01 mg/mL methamphetamine-d 14 and mescaline-d 9 were added to each sample for a final concentration of 0.25 mg/L. Negative and positive urine samples were extracted with each batch. Four drops of concentrated KOH and 5 mL of chlorobutane were added to all samples. Next, the samples were capped and mixed for 20 min. The samples were then centrifuged for 10 min at 3000 rpm. The top organic layer was transferred with a glass pipette to clean 10-mL conical test tubes. Prior to drying down under nitrogen at 40°C, 50 µL of 10% methanolic HCl was added to each sample. The eluates were reconstituted with 50 μL each of ethyl acetate and PFPA. All tubes were capped, vortex mixed, and incubated at 70°C for 15 min. The samples were again evaporated to dryness under nitrogen at 40°C, reconstituted with 25 μL ethyl acetate, and then transferred to glass autosampler vials.
Three microliters of sample was injected using a 10:1 split and an inlet temperature of 225°C. An initial oven temperature of 100°C was held for 1.5 min before ramping at 9°C/min to 235°C and then 35°C/min to 300°C. The column was held for 1.5 min at the final temperature of 300°C for a total run time of 19.8 min.
The confirmation criteria for acceptance of a positive screening result for the designer drug screen are the same as described for the basic drug screen.
BZP and TFMPP extraction
Two milliliters of sample, calibrators, and control were aliquoted, and 100 µL of the internal standard solution containing 0.01 mg/mL mCPP was added to each sample for a final concentration of 0.50 mg/L. The described designer drug screen liquid-liquid extraction procedure was used to extract samples for BZP and TFMPP confirmation. In the final step after derivatization with PFPA, the samples were evaporated to dryness under nitrogen at 55°C, reconstituted with 50 μL ethyl acetate, and transferred to glass autosampler vials.
One microliter of sample was injected using a pulsed split program of 40 psi for 1.0 min, at a 10:1 split, and an inlet temperature of 225°C. An initial oven temperature of 125°C was held for 3 min before ramping at 10°C/min to 200°C and then 40°C/min to 300°C. The column was held for 0.5 min at the final temperature of 300°C for a total run time of 13.5 min.
The identification criteria for acceptance and quantitation of a positive result for BZP and TFMPP are described. The retention time (t R ) of the analytes must be within ± 2% of the t R of the calibrator. Qualifier ion ratios of the analytes must be within ± 20% of the average ion ratios established from the calibrators. A chromatographic peak should be Gaussian in shape and baseline resolved from any interfering peaks.
mCPP extraction
Two milliliters of sample, calibrators, and control were aliquoted, and 100 µL of the internal standard solution containing 0.01 mg/mL TFMPP-d 4 was added to each sample for a final concentration of 0.50 mg/L. The described designer drug screen liquid-liquid extraction procedure was used to extract samples for the mCPP confirmation. In the last step after derivatization with PFPA, the samples were evaporated to dryness under nitrogen at 55°C, reconstituted with 50 μL ethyl acetate, and transferred to glass autosampler vials.
The identification criteria for acceptance and quantitation of a positive result for mCPP are the same as described for the BZP and TFMPP extraction.
Method validation
The linearity, the limit of detection (LOD), limit of quantitation (LOQ), and upper limit of linearity (ULOL) for the BZP, TFMPP, and mCPP methods were established with each extraction. The minimal criterion for acceptability of each method's linearity was to have a line of regression with a correlation coefficient (r 2 ) of 0.99 or greater. For each drug, a standard curve spiked with a linear range of 0.025-2.0 mg/L was used for quantitation. The LOD was defined as the lowest analyte concentration where all qualifier ion ratios were within ± 20% of the average ion ratios established from the calibrators. The LOQ was defined as the lowest analyte concentration where the measured value was within ± 20% of the theoretical concentration and all qualifier ion ratios were within ± 20% of the average ion ratios based on the calibrators. The ULOL was defined as the highest analyte concentration where the measured value was within ± 20% of the theoretical concentration and the qualifier ratios were within ± 20% of the average ion ratios based on the calibrators.
For these three extraction methods, the LOD and LOQ were 0.025 mg/L and the ULOL was 2.0 mg/L.
BZP, TFMPP, and mCPP cross-reactivity
As BZP, TFMPP, and mCPP have structural similarities to MDMA and other amine compounds, it was of interest to know if these designer drugs would cross-react with amphetamine or MDMA urine drug screening kits. The following urine drug screening assay kits were used: Roche Abuscreen Online ® Amphetamine (Indianapolis, IN), Siemens Emit ® II Plus Amphetamine (Newark, DE), and Microgenics DRI ® Ecstasy (Fremont, CA). Negative urine samples were fortified individually with BZP, TFMPP, and mCPP at concentrations ranging from 0.05 to 100 mg/L. The samples were analyzed using the Hitachi Modular P urine drug screening instrument. Both the amphetamine kits and the ecstasy kit were calibrated at 0.50 mg/L with d-amphetamine and MDMA, respectively.
Results
Initial screening for standard drugs of abuse panels were performed on the 251 urine specimens at the DoD drug testing laboratories. All of the urine specimens screened and rescreened positive by immunoassay for MDMA and were confirmed by GC-MS SIM for both MDMA and/or 3,4-methylenedioxyamphetamine (MDA). The percentage of confirmed samples for MDA was 92%. Additionally, some of the urine specimens screened positive by immunoassay for amphetamines and were confirmed by an isomeric GC-MS SIM method for d-amphetamine and/or d-methamphetamine (20) . The percentage of d-amphetamine and d-methamphetamine confirmed samples were 26% and 27%, respectively.
Next, special testing for designer drugs was performed at the DFT, AFMES. A full scan GC-MS designer drug screen detected the presence of BZP, TFMPP, and mCPP in 17%, 9%, and 2% of the urine specimens, respectively. None of the other 30 designer drugs were detected as listed in Table I . The full scan GC-MS spectra of BZP, TFMPP, and mCPP derivatized with PFPA can be seen in Figure 1 .
BZP and TFMPP were confirmed in 15% and 7% of the urine specimens, respectively. The BZP and TFMPP concentrations ranged from 0.029 to 68.655 mg/L and 0.025 to 11.365 mg/L, respectively. mCPP was confirmed in 1% of the urine specimens. The concentrations for mCPP ranged from 0.075 to 0.166 mg/L. Spiked BZP, TFMPP, and mCPP urine samples screened negative for both the Siemens Emit II Plus Amphetamine and Microgenics DRI Ecstasy screening assays. Also, the BZP samples screened negative for the Roche Abuscreen Online Amphetamine screening assay. Two specimens, spiked individually, at 0.90 mg/L mCPP and 0.275 mg/L TFMPP, screened positive with the Roche Amphetamine screening assay.
Discussion
The DoD drug testing laboratories receive specimens that are collected for random urine analysis and tested using a routine standard drugs of abuse panel, which includes MDMA testing. It is reasonable to assume, that confirmed ecstasy users are potentially consuming ecstasy mimic or combination tablets that contain other designer drugs. Therefore, a targeted popu- lation of MDMA-positive urine specimens were chosen for this study. Initially, these urine samples were tested with a full scan GC-MS designer drug screen which had the ability to detect 33 designer drugs as shown in Table I . If any unidentifiable peaks were detected in the GC-MS designer drug screen, the urine sample was extracted using a full scan GC-MS basic drug screen extraction. Additionally, if any urine samples screened positive for mCPP, they were re-extracted and analyzed using a basic drug screen extraction to detect trazodone and nefazodone. If either drug was detected in the GC-MS basic drug screen, then the presence of mCPP was attributed to the metabolism of trazodone and nefazodone (21) . Because these urine specimens were MDMA-positive and a prescription history was available, the presence of mCPP was assumed to be from ecstasy mimic or combination tablets that contained mCPP. For the BZP and TFMPP quantitative procedure, mCPP was used as the internal standard because it is similar in structure and at the time of method development TFMPP-d 4 and BZP-d 7 were not available for purchase. Based on the designer drug screen results, mCPP was not detected in the urine specimens that contained BZP and TFMPP. In the future, the deuterated piperazine derivatives will be used as internal standards for the BZP and TFMPP quantitative procedure in place of mCPP. The internal standard used for the mCPP quantitative procedure was TFMPP-d 4 because it is similar in structure and was available, and a deuterated standard of mCPP was not available.
BZP was confirmed in 15% of the urine samples, and TFMPP was confirmed in 7%. TFMPP was only detected in samples that contained BZP. No concentration correlation was determined between BZP and TFMPP except that the concentration of BZP was always greater than the concentration of TFMPP. The ratios of BZP/TFMPP ranged from 4:1 to 92:1. mCPP was confirmed in 1% of the urine samples. In the samples that contained mCPP, neither BZP nor TFMPP was detected.
Thirty-six percent of the samples contained a stimulant or psychoactive component other than MDMA and MDA. These drugs included BZP, TFMPP, mCPP, amphetamine, and methamphetamine. According to reports from the GBI and the Drug Enforcement Administration (DEA), MDA and methamphetamine have been detected in seized ecstasy tablets, but amphetamine has not (1, 22) . Therefore, MDA detected in the urine samples could be attributed to metabolism or presence of the drug in the tablet, whereas amphetamine is most likely present due to metabolism only (21) . Additional drugs that were detected in the full scan GC-MS designer drug and basic drug screens included caffeine, dextromethorphan, chlorpheniramine, pseudoephedrine, and phenylpropanolamine. These various drug compounds and percentages detected can be seen in Figure 2 .
Based on the cross-reactivity results, BZP, TFMPP, and mCPP positive specimens may be undetected by immunoassay screening. A sample containing these compounds may produce a positive screening result for amphetamines and confirm negative by a GC-MS SIM amines method. Instead, a full scan GC-MS basic drug screen can be used to detect these piperazine derivative designer drugs (19, 23) . This however, is not a common initial testing approach at high throughput laboratories. Shown in Figure 3 are the full scan GC-MS mass spectra of BZP, TFMPP, and mCPP as detected in a basic drug screen extraction.
Conclusions
Overall, 36% of the specimens contained a stimulant or psychoactive component other than MDMA and MDA. Sixteen percent of the MDMA-positive urine samples contained the following piperazine derivative designer drugs: BZP and TFMPP (15%), and mCPP (1%). Routine analysis at forensic urine drug testing laboratories would not be able to detect these designer drugs. The increase in popularity and availability of these designer drugs can be seen from the increased number of seizures. If illicit drug manufacturers continue to produce piperazine derivative designer drugs without the presence of MDMA, the use of these compounds could go undetected. This study shows a connection between the increased confiscations and actual use of these piperazine derivative designer drugs.
